Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5678 plus Cemiplimab in Metastatic Castration-resistant Prostate Cancer
NCT06826768Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nezastomig in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
nezastomig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06826768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826768.